Page 1

4DMedical ™ ASX announcement ASX : 4DX For personal use only Quarterly Activity Report and Appendix 4C for Q1 FY2022 25 October 2021 Highlights • 4DMedical broadened its potential commercialisation pathways beyond hospitals and healthcare imaging networks when it signed a contract with multinational pharmaceutical company , Novartis , to use XV Lung Ventilation Analysis Software ( XV LVAST ) in a U.S. pharmaceutical - led clinical program to validate therapies to treat chronic obstructive pulmonary disease ( COPD ) • Successful completion of Phase One of 4DMedical's XV LVAS clinical pilot program with I- MED Radiology Network ( I - MED ) with overwhelmingly positive feedback from radiologists and patients . Phase Two will be completed over the remaining year to assess a potential commercial partnership Partnered with Kailo Medical to automate the processing of information from X - ray equipment at Australian healthcare centres , generating XV LVAS reports in the cloud Clinical trial data expected to be announced at international medical conferences over the next quarter Strong cash position with $ 72.2 million held at 30 September 2021 4DMedical Limited ( ASX : 4DX , “ 4DMedical ” , or the “ Company ” ) , a medical technology company focused on commercialising its FDA - cleared and TGA- approved respiratory imaging platform , is pleased to release its Quarterly Activity Report and Appendix 4C Cash Flow Report for the quarter ending 30 September 2021 . Contract with Novartis In August 2021 , the Company announced that it had signed its first pharmaceutical - focused contract with Novartis for the commercial use of 4DMedical's XV Lung Ventilation Analysis Software ( XV LVASTM ) . As one of the world's largest pharmaceutical developers and producers , Novartis will use XV LVAS to assess patient outcomes as part of a clinical program focused on novel therapies to treat Chronic Obstructive Pulmonary Disease ( COPD ) – the third highest cause of death in the world . The clinical program with Novartis will be conducted at the University of Miami in the U.S. , under 4DMedical's Functional Lung Imaging Research Program to advance breakthrough lung technologies . The contract is not material in terms of revenue , however , it does expand the Company's commercial product offering to the pharmaceutical and medical device industries . Clinical pilot program with I - MED Radiology Network Following the successful completion of Phase One of its clinical pilot with I - MED Radiology Network ( I - MED ) in Victoria , the Company announced the commencement of Phase Two . I - MED is Australia's largest outsourced provider of radiology , with more than 200 clinics nationwide , offering a range of diagnostic imaging services to private and public hospitals . Phase One of the clinical pilot involved implementing XV LVAS at an I - MED imaging clinic in Melbourne , where patients with various respiratory diseases were referred a scan and radiologists The future of lung health Melbourne 5/468 St. Kilda Rd , Melbourne , Victoria , 3004 Tel : +61 ( 3 ) 9545 5940 Los Angeles 21600 Oxnard St # 300 , Woodland Hills , 91367 , CA Tel : +1 ( 818 ) 794-6467 4DMedical Limited ABN : 31 161 684 831 Email : info@4DMedical.com www.4DMedical.com 1